SSGJ-621

N/A

Report date: 2024/02/21 14:43:37

Base Information

Drug NameSSGJ-621
Drug Alias NameSSGJ-621621
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Interleukin-33
TargetsInterleukin-33
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A